-
Substance Abuse Treatment Market to Flourish at 12.50% CAGR, Reaching 23.38 Billion USD by 2032
21 Jan 2025 14:30 GMT
… market includes
Pfizer Inc.
Alkermes Plc
GlaxoSmithKline Plc.
Purdue Pharma … Trending Industry Reports:
Glycopeptide Antibiotic Industry Outlook 2025 - https … #47;reports/glycopeptide-antibiotic-market-37328
Gastric Electric Stimulator …
-
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement
09 Feb 2021 16:49 GMT
… )
AEterna Zentaris Inc. (NASDAQ: AEZS)
Alkermes Plc (NASDAQ: ALKS)
AngioDynamics, Inc. (NASDAQ: ANGO … of commercial promotion of its antibiotic Nuzyra into community setting)
Profound …
-
Sustained Release Excipients Market is Projected to Register 7.1% CAGR till 2026
03 Nov 2020 12:55 GMT
… diseases has also resulted in antibiotic resistance, which negatively affects the … physicians in order to combat antibiotic resistance. Since these formulations create … Corporation; Orbis Biosciences, Inc.; and Alkermes plc.
-
Big Pharma Money On Shaky Ground, And A Look At Assembly Biosciences: The Good, Bad, And Ugly Of Biopharma
24 Oct 2019 17:30 GMT
… not eliminate the virus. Alkermes still offering speculative entry … 8-K filing by Alkermes Plc (ALKS) revealed that the company … development and commercialization of antibiotic therapies based on the … intravenous (IV) and oral antibiotic for the treatment of …
-
Sustained Release Excipients Market Size will Exhibit 7.1% CAGR till 2026
11 Jun 2019 13:14 GMT
… diseases has also resulted in antibiotic resistance, which negatively affects the … physicians in order to combat antibiotic resistance. Since these formulations create … Corporation; Orbis Biosciences, Inc.; and Alkermes plc.
Grand View Research has segmented …
-
Global Sustained Release Excipients Market Analysis & Forecast Report 2015-2018 & 2026: Increasing Focus on Novel Drug Delivery R&D and Rising Adoption of Extended Release Formulations
16 Nov 2018 14:45 GMT
… diseases has also resulted in antibiotic resistance, which negatively affects the … physicians in order to combat antibiotic resistance. Since these formulations create … Corporation; Orbis Biosciences, Inc.; and Alkermes plc.
Key Topics Covered:
Chapter 1 …
-
Oklahoma Medicaid tests new tactic to curb U.S. drug costs
23 Aug 2018 14:09 GMT
… contract under this strategy with Alkermes Plc for injected schizophrenia treatment Aristada … new agreements for an expensive antibiotic and an epilepsy drug, Nancy …
-
Week Ahead In Pharmaceuticals - Stocks To Watch
07 Jul 2018 15:32 GMT
… .
On the regulatory front, Alkermes Plc's (ALKS) ARISTADA INITIO, a long … candidate is Neutrolin, a non-antibiotic anti-infective developed as a …
-
3 Things In Biotech, April 28: Fighting Mental Disorders, And A New Strategy For Bacteria?
29 Apr 2018 12:34 GMT
… Company: Achaogen (AKAO) Therapy: Antibiotics Disease: Bacterial infection News: AKAO … research into an aminoglycoside antibiotic with the goal of … study Company: Alkermes plc (ALKS) Therapy: ALKS 3831 Disease: Schizophrenia News: ALKS announced that …
-
Your Daily Pharma Scoop: Geron Debates, Flexion Moves Up, Axsome Proceeds To Trial
27 Apr 2018 12:35 GMT
… its components. In other news Alkermes Plc (NASDAQ:ALKS) completed enrollment in a … that helps early developers of antibiotics. The funds will go towards … next-generation broad-spectrum aminoglycoside antibiotic capable of overcoming drug-resistant …